Liu Angela M, Wong Kwong-Fai, Jiang Xiaoou, Qiao Yiting, Luk John M
Department of Pharmacology, National University of Singapore, Singapore.
Biochim Biophys Acta. 2012 Dec;1826(2):357-64. doi: 10.1016/j.bbcan.2012.05.006. Epub 2012 Jun 7.
Hippo pathway, originally discovered in Drosophila, is responsible for organ size control. The pathway is conserved in mammals and has a significant role in restraining cancer development. Regulating the Hippo pathway thus represents a potential therapeutic approach to treat cancer, which however requires deep understanding of the targeted pathway. Despite our limited knowledge on the pathway, there are increasing discoveries of new molecules that regulate and modulate the Hippo downstream signaling particularly in various solid malignancies, from extracellular stimuli or via pathway crosstalk. Herein, we discuss the roles of newly identified and key regulators that connect with core components (MST1/2, LATS1/2, SAV1, and MOB1) and downstream effector (YAP) in the Hippo pathway having an important role in cancer development and progression. Understanding of the mammalian Hippo pathway regulation may shed new insights to allow us selecting the right oncogenic targets and designing effective drugs for cancer treatments.
河马通路最初是在果蝇中发现的，负责器官大小的控制。该通路在哺乳动物中保守，在抑制癌症发展中具有重要作用。因此，调节河马通路代表了一种治疗癌症的潜在方法，然而这需要对靶向通路有深入的了解。尽管我们对该通路的了解有限，但越来越多的新分子被发现可调节和调控河马通路的下游信号，特别是在各种实体恶性肿瘤中，这些新分子来自细胞外刺激或通过通路间的相互作用。在此，我们讨论新鉴定的关键调节因子的作用，这些调节因子与河马通路中的核心成分（MST1/2、LATS1/2、SAV1和MOB1）以及下游效应因子（YAP）相关联，它们在癌症发展和进展中起着重要作用。对哺乳动物河马通路调节的理解可能会带来新的见解，使我们能够选择正确的致癌靶点并设计有效的癌症治疗药物。
